乳腺癌肝转移患者化疗后维持治疗的疗效及安全性研究  

Effects and safety of capecitabine maintenance therapy after combination chemotherapy for patients with breast cancer liver metastasis

作　　者：王峥[1] 陈洪志[1] 董济民[1] 马小斌[1] 林帅[1] 康华峰[2] 

机构地区：[1]西安市中心医院,西安710004 [2]西安交通大学第二附属医院肿瘤科

出　　处：《陕西医学杂志》2016年第10期1313-1315,共3页Shaanxi Medical Journal

摘　　要：目的:评价乳腺癌肝转移患者化疗临床获益后卡培他滨维持治疗的疗效及安全性。方法:乳腺癌肝转移患者53例,给予多西他赛、吉西他滨或长春瑞滨联合卡培他滨化疗,疾病控制患者给予卡培他滨2000mg/(m^2·d)维持治疗,连用14d,21d为1周期,直至PD或不良反应不能耐受。主要观测指标为至疾病进展时间(TTP)和有效率(RR),并记录不良反应。结果:53例患者247周期化疗,中位化疗数为4周期。其中CR 7例(13.21%),PR 22例(41.51%),SD 15例(28.30%),PD 9例(13.21%),RR为54.72%(29/53),疾病控制率(DCR,DCR=CR+PR+SD)为83.02%(44/53)。给予卡培他滨单药维持治疗至PD,中位TTP为9.5个月。主要不良反应为骨髓抑制及手足综合征。结论:乳腺癌肝转移患者采用含卡培他滨联合化疗方案达到缓解或稳定后给予卡培他滨维持化疗,患者耐受性及安全性良好,TTP明显延长。Objective：To investigate the therapeutic effects and safety of capecitabine maintenance treatment for patients with breast cancer liver metastasis after combination chemotherapy.Methods：All the 53 patients received doxcetaxal,gemcitabine or vinorelbine combined capecitabine chemotherapeutic regime,patients with clinical benefit received capecitabine maintenance therapy until disease progressed or toxicity could not be tolerated.The response rate（RR）,time to progress（TTP）and adverse reactions and were recorded.Results：All the 53 cases of breast cancer liver metastasis received combined chemotherapy for 247 cycles with 7cases of CR（13.21%,7/53）,22 cases of PR（41.51%,22/53）,15 cases of SD（28.30%,15/53）,the response rate（RR,RR=CR＋PR）wasR54.72%（29/53）,disease control rate（DCR,DCR=CR＋PR＋SD）was 83.02%（44/53）,patients with disease control were administered capecitabine maintenance therapy until PD,the median TTP was 10.0months.Main treatment related adverse reaction was hand-foot syndrome and leucopenia.Conclusion：Capecitabine as maintenance treatment followed combined chemotherapy is an effective and safe method for breast cancer liver metastasis with good tolerability.

关 键 词：乳腺肿瘤/药物疗法 肝肿瘤/继发性 预后 @卡培他滨 

分 类 号：R737.9[医药卫生—肿瘤]